AAPL 192.4902 0.7591% MSFT 429.38 0.9498% GOOG 179.04 0.325% GOOGL 177.45 0.2996% AMZN 182.02 -0.8282% NVDA 947.4001 -0.0422% META 464.53 -0.9193% TSLA 186.0554 6.3478% TSM 153.42 -0.0847% LLY 803.85 2.6392% V 276.17 -0.8509% AVGO 1399.41 -1.0339% JPM 198.68 1.585% UNH 522.2967 0.9796% NVO 134.5401 1.2265% WMT 64.9 1.1218% LVMUY 166.815 -1.2052% XOM 118.03 -0.5393% LVMHF 846.034 0.1224% MA 457.885 -0.3862%

Oxford BioDynamics Plc

Healthcare US OXBOF

0.15USD
-(-%)

Last update at 2024-05-20T13:30:00Z

Day Range

0.150.15
LowHigh

52 Week Range

0.130.60
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Income before tax -7.56700M -7.62900M -4.91000M -3.38600M -2.42300M
Minority interest 0.00000M - 0.02M 0.02M 0.02M
Net income -6.71000M -6.68200M -4.31300M -2.80000M -1.95300M
Selling general administrative 2.45M 1.85M 1.32M 1.42M 1.08M
Selling and marketing expenses - - - - -
Gross profit 0.12M -0.55700M -0.16600M 0.44M 0.49M
Reconciled depreciation 1.21M 1.09M 0.47M 0.39M 0.33M
Ebit -8.46700M -7.48100M -4.83000M -3.38600M -2.42300M
Ebitda -7.25400M -6.39300M -4.36300M -2.99900M -2.09200M
Depreciation and amortization 1.21M 1.09M 0.47M 0.39M 0.33M
Non operating income net other - - - - -
Operating income -8.60100M -7.51200M -4.95100M -3.72300M -2.60200M
Other operating expenses 8.76M 7.85M 5.41M 4.63M 3.79M
Interest expense 0.20M 0.15M 0.08M 0.00000M 0.00000M
Tax provision -0.85700M -0.94700M -0.59700M -0.58600M -0.47000M
Interest income 0.13M 0.03M 0.12M 0.20M 0.09M
Net interest income -0.06100M -0.11700M 0.10M 0.20M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.85700M -0.94700M -0.59700M -0.58600M -0.47000M
Total revenue 0.15M 0.34M 0.46M 0.91M 1.19M
Total operating expenses 8.72M 6.96M 4.79M 4.16M 3.10M
Cost of revenue 0.04M 0.90M 0.62M 0.47M 0.69M
Total other income expense net 1.03M -0.11700M 0.04M 0.34M 0.18M
Discontinued operations - - - - -
Net income from continuing ops -6.71000M -6.68200M -4.31300M -2.80000M -1.95300M
Net income applicable to common shares -6.71000M -6.68200M -4.34900M -2.80000M -1.95300M
Preferred stock and other adjustments - - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Total assets 11.34M 15.38M 15.35M 18.79M 20.94M
Intangible assets 1.60M 1.15M 0.87M 0.56M 0.35M
Earning assets - - - - -
Other current assets - - - - -
Total liab 8.76M 8.69M 1.77M 1.20M 0.89M
Total stockholder equity 2.59M 6.68M 13.56M 17.57M 20.03M
Deferred long term liab - - - - -
Other current liab 0.17M 0.29M 0.06M 0.03M 0.05M
Common stock 1.00M 0.93M 0.93M 0.93M 0.93M
Capital stock 1.00M 0.93M 0.93M 0.93M 0.93M
Retained earnings -20.70900M -14.17100M -7.31400M -3.08200M -0.47200M
Other liab 0.45M 0.44M 0.07M 0.09M 0.07M
Good will - - - - -
Other assets - - - - -
Cash 0.97M 2.17M 6.12M 5.20M 18.28M
Cash and equivalents - - - - -
Total current liabilities 2.91M 2.29M 1.29M 1.11M 0.82M
Current deferred revenue - - - - -
Net debt 5.16M 4.41M -5.57800M -5.19800M -18.27800M
Short term debt 0.74M 0.63M 0.13M - -
Short long term debt - - - - -
Short long term debt total 6.14M 6.59M 0.54M - -
Other stockholder equity 22.29M 19.92M 19.95M 19.73M 19.58M
Property plant equipment 6.98M 7.55M 1.18M 0.89M 0.97M
Total current assets 2.77M 6.68M 12.88M 16.92M 19.62M
Long term investments - - - - -
Net tangible assets 0.99M 5.52M 12.27M 17.02M 19.68M
Short term investments 0.03M 2.16M 5.39M 10.30M -
Net receivables 1.43M 1.71M 0.83M 0.93M 1.05M
Long term debt - - - - -
Inventory 0.34M 0.39M 0.32M 0.24M 0.15M
Accounts payable 2.00M 1.66M 1.10M 1.08M 0.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 5.39M 10.30M -
Deferred long term asset charges - - - - -
Non current assets total 8.58M 8.70M 2.47M 1.87M 1.32M
Capital lease obligations 6.14M 6.59M 0.54M - -
Long term debt total - - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-09-30
Investments 1.25M 3.22M 4.91M -10.72200M -10.72200M
Change to liabilities 0.47M 0.42M 0.17M 0.38M -0.31600M
Total cashflows from investing activities 1.25M 2.83M 4.58M -11.18900M -0.67800M
Net borrowings -0.70300M -0.80400M -0.18100M -0.18100M -0.18100M
Total cash from financing activities 2.56M -0.80400M -0.18100M 0.24M 10.04M
Change to operating activities - - - - -
Net income -7.56700M -7.62900M -4.91000M -3.38600M -2.42300M
Change in cash -1.20100M -3.94400M 0.92M -13.08000M 7.48M
Begin period cash flow 2.17M 6.12M 5.20M 18.28M 10.79M
End period cash flow 0.97M 2.17M 6.12M 5.20M 18.28M
Total cash from operating activities -5.17700M -5.91800M -3.40100M -2.27100M -1.94200M
Issuance of capital stock 3.62M - 0.00000M 0.24M 10.04M
Depreciation 1.21M 1.09M 0.47M 0.39M 0.33M
Other cashflows from investing activities 0.01M 2.69M 0.12M 0.17M 0.09M
Dividends paid - - - - -
Change to inventory 0.06M -0.06900M -0.08000M -0.09700M -0.05600M
Change to account receivables 0.47M -0.56000M 0.14M -0.01400M -0.10000M
Sale purchase of stock - - - - -
Other cashflows from financing activities -1.06100M 2.83M 4.58M -11.18900M -0.00700M
Change to netincome -0.67900M -0.11100M 0.26M -0.12800M 0.15M
Capital expenditures 0.90M 3.09M 0.46M 0.63M 0.78M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.00M -0.21300M 0.24M 0.27M -0.47200M
Stock based compensation 0.39M 0.25M 0.25M 0.27M 0.20M
Other non cash items -0.21600M 0.58M 0.55M 0.18M 0.43M
Free cash flow -6.07800M -9.00700M -3.85800M -2.90300M -2.71800M

Fundamentals

  • Previous Close 0.15
  • Market Cap69.28M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.67200M
  • Revenue TTM0.29M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.12M
  • Diluted EPS TTM-0.09

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OXBOF
Oxford BioDynamics Plc
- -% 0.15 - - 230.24 5.92 249.12 -9.3721
NVO
Novo Nordisk A/S
1.63 1.23% 134.54 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
1.54 1.16% 134.67 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.66 1.49% 439.21 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd
-0.16 0.17% 92.58 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

Oxford BioDynamics Plc

3140 Rowan Place, Oxford, United Kingdom, OX4 2WB

Key Executives

Name Title Year Born
Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. CEO & Director 1963
Mr. Paul Leslie Stockdale F.C.A., M.A. CFO & Director 1975
Dr. Alexandre Akoulitchev Ma (Oxon), Ph.D. Chief Scientific Officer & Director 1962
Mr. Thomas G. Guiel B.A. Chief Operating Officer NA
Dr. Jayne Green B.Sc., Ph.D. Director of Operations NA
Dr. Ewan Hunter B.Sc., BSC, Ph.D., Ph.D., (KCL) C.D.O NA
T. Demain Company Sec. NA
Dr. Steven Tucker M.D., FACP Group Clinical Director NA
Prof. Siamon Gordon Clinical Director of Inflammation & Infection NA
Dr. Sandy Primrose Ph.D. Technical Consultant NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).